Pagină 1 din 20 rezultate
This invention relates to pharmaceutical compounds and to compositions containing them, being primarily concerned with substances of use in the therapy of cancers senstive to those compounds and compositions, of certain non-malignant forms of proliferative disease such as psoriasis, and of certain
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of bone and cartilage physiology as well as the treatment of tumors and cysts. More specifically, the invention refers to the use of a formulation for the growth of bone and cartilage and the
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates generally to the fields of bone and cartilage physiology as well as the treatment of tumors and cysts. More specifically, the invention refers to the use of a formulation for the growth of bone and cartilage and the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of bone and cartilage physiology as well as the treatment of tumors and cysts. More specifically, the invention refers to the use of a formulation for the growth of bone and cartilage and the
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
None
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention refers to production of a synthetic compound termed 4,4'-(4'-Carboxy)-4-nonyloxy-[1,1'-biphenyl]-3,5-diyl)dibutanoic acid (hereinafter referred to as "CNBDA"),
BACKGROUND OF THE INVENTION
Transferrin is a protein found in the blood of all humans and its known function is to carry iron to those organs and cells of the body that require this metal for normal function. Recently, scientists have reported that an important function of iron carried by
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 35 U.S.C. .sctn. 371 National Phase Entry Application from PCT/KR2013/007852, filed on Aug. 30, 2013, and designating the United States, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention
This invention relates to pharmaceutical compounds and to compositions containing them, being primarily concerned with substances of use in the therapy of cancer including leukaemia, of certain non-malignant forms of proliferative disease such as psoriasis, and of certain inflammatory conditions
This invention relates to pharmaceutical compounds and to compositions containing them, being primarily concerned with substances of use in the therapy of cancer including leukaemia, of certain non-malignant forms of proliferative disease such as psoriasis, and of certain inflammatory conditions
This invention relates to pharmaceutical compounds, to processes for their preparation and to compositions containing them, and is primarily concerned with substances having activity in relation to certain forms of cancer, including leukemia, and certain non-malignant forms of proliferative
TECHNICAL FIELD
This invention is in the field of anthracycline chemistry. More particularly, it concerns analogs of doxorubicin and daunorubicin that are useful antitumor agents.
BACKGROUND ART
Doxorubicin (adriamycin) is widely used as an antitumor agent in the treatment of a wide range of solid
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national stage application under 35 U.S.C. 371 and claims the benefit of PCT Application No. PCT/GB2011/051162 having an international filing date of Jun. 21, 2011, which designated the United States, which PCT application claimed the
The present invention relates to pyrimido[5,4-d]pyrimidines of the general formula ##STR2## their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which have valuable pharmacological properties, in particular
BACKGROUND OF THE INVENTION
N-6 cyclopropylPMEDAP ("cpr-PMEDAP") has been shown to be effective producing an antiproliferative and differentiation-inducing effect in in vitro cell culture against a variety of tumor cell lines (Naessens et al., "Biochem. Pharmacol. 1999 Jul. 15; 58(2):311-23).
TECHNICAL FIELD
The invention relates to compounds useful in the treatment of inflammation, allergic reactions, autoimmune diseases, cancer, and similar other conditions that are cell adhesion-dependent. More specifically, the invention concerns compounds, containing GalNAc lewis.sup.x as a mucin